EMLA cream application without occlusive dressing before upper facial botulinum toxin injection: a randomized, double-blind, placebo-controlled trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 18362558.
- Also identified by DOI 10.1097/SAP.0b013e31812f6e0f.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A randomized, double-blind, placebo-controlled clinical trial was conducted among 44 subjects to assess the efficacy of EMLA cream application without occlusive dressing on pain on needling (PN) and pain on injection (PI) felt during multiple botulinum toxin type A (BTA) injections for correction of hyperkinetic upper facial lines. Mean PN score was less than PI score with high correlation and no significant difference. Although both PN and PI scores (visual analog) were less in the EMLA than placebo group, the difference was only statistically significant for PN score. Time intervals between the cream application and BTA injections beyond 60 minutes did not show lower pain score in either type of the pain.
Medical subject headings
- Anesthetics, Local
- Botulinum Toxins, Type A
- Lidocaine
- Neuromuscular Agents
- Prilocaine
- Skin Aging